A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

Amblyopia Clinical Trial

— ATS22  

Official title:

A Randomized Trial to Evaluate Sequential vs Simultaneous Spectacles Plus Patching for Amblyopia in Children 3 to <13 Years Old

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04378790
• Other study ID #: ATS22
• Secondary ID: 2UG1EY011751
• Status: Recruiting
• Phase: N/A
• Start date: December 8, 2020
• Est. completion date: June 2025

Study information

• Verified date: February 2024
• Source: Jaeb Center for Health Research
• Contact: Raymond T Kraker, MSPH
• Phone: 813-975-8690
• Email: rkraker[@]jaeb.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to <13 years of age.

Description:

At an enrollment visit, distance VA will be measured in trial frames with or without cycloplegia based on a cycloplegic refraction performed within 30 days. If still apparently eligible, children will be prescribed spectacles and will then return for a spectacle baseline visit, where they will wear their new spectacles for the first time for at least 10 minutes (but no more than 24 hours) and will be tested in those new spectacles to confirm final eligibility prior to randomization.

Participants not found to be eligible in their new spectacles will end study participation. Participants eligible for the study will be randomly allocated to one of two treatment groups: Sequential (spectacles alone) and then patching if needed (monitored by ODM), or Simultaneous (spectacles and patching monitored by ODM).

After randomization, follow-up visits will occur at 8-week intervals through 56 weeks. At each visit on or after the 8-week visit, participants will be classified as either: stable/worsening or improving; those stable/worsening are then classified as having either resolved or residual amblyopia, provided that the current and most recent previous visit were completed at least 6-weeks apart (target 8 weeks) and provided the required test and retest VA testing was completed. Participants who are stable/worsening and have residual amblyopia in the sequential group will start patching (monitored by ODM) and continue to be followed every 8 weeks. Participants in the simultaneous group, or in the sequential group after having advanced to patching, who are stable/worsening but have residual amblyopia will be released to treatment at investigator discretion.

All participants continue 8-weekly visits until 56 weeks when Study participation ends.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 544
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 13 Years

Eligibility

Inclusion Criteria:

1. Age 3 to <13 years at the time of randomization

2. Amblyopia associated with anisometropia, strabismus, or both

o Criteria for strabismic amblyopia: At least one of the following must be met:

• Presence of a heterotropia on examination at distance or near fixation (with or without optical correction)

• Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia)

• Criteria for anisometropia: At least one of the following criteria must be met:

• 1.00 D difference between eyes in spherical equivalent (SE)

• 1.50 D difference in astigmatism between corresponding meridians in the two eyes

• Criteria for combined-mechanism amblyopia: Both of the following criteria must be met:

• Criteria for strabismus are met (see above)

• 1.00 D difference between eyes in spherical equivalent OR =1.50 D difference in astigmatism between corresponding meridians in the two eyes

3. No previous treatment for amblyopia, including no more than 24 hours of spectacle wear.

4. Investigator planning to initiate spectacle correction of refractive error meeting the following criteria based on a cycloplegic refraction that has been performed within 30 days:

1. Full correction of anisometropia

2. Full correction of astigmatism with the same axis found by the cycloplegic refraction

3. Full correction of any myopia

4. Hyperopia must not be under corrected by more than 1.50 D, and reduction in plus sphere must be symmetric in the two eyes.

5. At enrollment, single VA measured in each eye assessed in trial frames with the spectacle correction the investigator plans to prescribe, using the investigator's routine method as follows:

• VA in the amblyopic eye 20/40 to 20/200 inclusive.

• Age-normal VA in the fellow eye:40,41

• 3 years: 0.4 logMAR (20/50) or better

• 4 years: 0.3 logMAR (20/40) or better

• 5-6 years: 0.2 logMAR (20/32) or better

• 7-12 years: 0.12 logMAR (78 letters) or better

• Interocular difference = 3 logMAR lines (0.3 logMAR) or = 15 letters o When participants return for the Spectacle Baseline / Randomization Visit with their new spectacles, they will need to meet the same criteria as above using the ATS-HOTV or E-ETDRS protocol after wearing the new spectacles for at least 10 minutes (based upon the mean of a test and retest of VA in those new spectacles).

6. Investigator is willing to prescribe spectacle wear followed sequentially by patching or simultaneous spectacles and patching treatment per protocol.

7. Parent understands the protocol and is willing to accept randomization.

8. Parent has phone (or access to phone) and is willing to be contacted by Jaeb Center staff or other study staff.

9. Relocation outside of area of an active PEDIG site for this study within the next 56 weeks is not anticipated.

Exclusion Criteria:

1. Myopia greater than -6.00 D spherical equivalent in either eye.

2. Previous intraocular or refractive surgery.

3. Planned strabismus surgery in the next 56 weeks.

4. Any previous treatment for amblyopia (patching, atropine, Bangerter filter, vision therapy, or binocular treatment).

5. Previous spectacle or contact lens wear for more than 24 hours.

6. Parent and participant willing to forego option of contact lens wear for the duration of the study.

7. Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above VA criteria are met).

8. Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities or attention deficit hyperactivity disorder (ADHD) are not excluded.

9. Known allergy to adhesive patches.

10. Known allergy to silicone.

Related Conditions & MeSH terms

• Amblyopia

Intervention

Other:
• Patching
Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
• Glasses
Eye Glasses are created and worn by patient to improve vision

Locations

Country	Name	City	State
United States	River View Family Eyecare	Albany	Oregon
United States	Wilmer Eye Institute	Baltimore	Maryland
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Indiana School of Optometry	Bloomington	Indiana
United States	St Luke's Hospital	Boise	Idaho
United States	Boston Children's Hospital Waltham	Boston	Massachusetts
United States	Boston Medical Center	Boston	Massachusetts
United States	Ross Eye Institute, University of Buffalo, Med School Dept Ophthalmology	Buffalo	New York
United States	University of North Carolina	Chapel Hill	North Carolina
United States	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Ticho Eye Associates	Chicago Ridge	Illinois
United States	Cincinnati Children's Hospital	Cincinnati	Ohio
United States	Ohio State University College of Optometry	Columbus	Ohio
United States	Midwestern U Chicago College of Optometry	Downers Grove	Illinois
United States	Duke University Eye Center	Durham	North Carolina
United States	Pediatric Ophthalmology of Erie	Erie	Pennsylvania
United States	Nova Southeastern University College of Optometry, The Eye Institute	Fort Lauderdale	Florida
United States	Pediatric Eye Specialists, LLP	Fort Worth	Texas
United States	Marshall B. Ketchum University	Fullerton	California
United States	Midwestern University Eye Institute	Glendale	Arizona
United States	Helen DeVos Children's Hospital Pediatric Ophthalmology	Grand Rapids	Michigan
United States	Baylor College of Medicine	Houston	Texas
United States	Indiana University School of Optometry	Indianapolis	Indiana
United States	Nemours Children's Clinic	Jacksonville	Florida
United States	Children's Mercy Hospitals and Clinics	Kansas City	Missouri
United States	Conestoga Eye	Lancaster	Pennsylvania
United States	Snowy Range Vision Center	Laramie	Wyoming
United States	Progressive Eye Care	Lisle	Illinois
United States	Loma Linda University Health Care, Dept. of Ophthalmology	Loma Linda	California
United States	Texas Tech University Health Science Center	Lubbock	Texas
United States	Southern College of Optometry	Memphis	Tennessee
United States	Eye Physicians & Surgeons, PC	Milford	Connecticut
United States	Vanderbilt University Medical Center - Vanderbilt Eye Institute	Nashville	Tennessee
United States	State University of New York, College of Optometry	New York	New York
United States	Virginia Pediatric Eye Center	Norfolk	Virginia
United States	Dean A. McGee Eye Institute	Oklahoma City	Oklahoma
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Stanford University	Palo Alto	California
United States	Salus University/Pennsylvania College of Optometry	Philadelphia	Pennsylvania
United States	Wills Eye Hospital	Philadelphia	Pennsylvania
United States	Western University College of Optometry	Pomona	California
United States	Mayo Clinic	Rochester	Minnesota
United States	St. Louis Children's Hospital Eye Center	Saint Louis	Missouri
United States	U of MO St. Louis College of Optometry	Saint Louis	Missouri
United States	Rocky Mountain Eye Care Associates	Salt Lake City	Utah
United States	San Antonio Eye Center	San Antonio	Texas
United States	University of Incarnate Word Rosenberg School of Optometry	San Antonio	Texas
United States	PineCone Vision Center	Sartell	Minnesota
United States	Seattle Children's Hospital, University of Washington	Seattle	Washington
United States	Spokane Eye Clinical Research	Spokane	Washington
United States	University of Arizona	Tucson	Arizona
United States	Wolfe Eye Clinic	West Des Moines	Iowa

Sponsors (3)

Lead Sponsor	Collaborator
Jaeb Center for Health Research	National Eye Institute (NEI), Pediatric Eye Disease Investigator Group

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Amblyopic Eye logMAR distance Visual Acuity	Amblyopic eye VA (calculated as mean of test and retest) at the last visit that was the basis for a "stable resolved" or "stable residual" determination (in the sequential group, stable residual amblyopia criteria can be reached only after patching has been instituted); or; 56-week visit amblyopic-eye VA (calculated as mean of test and retest) in those completing a 56-week visit without ever meeting criteria for "stable resolved" or "stable residual" amblyopia (if retest missing at 56 weeks, the single test value will be used).	56 weeks
Secondary	Pediatric Eye Questionnaire (PedEyeQ)	Rasch scores for each questionnaire item will be obtained from published look-up tables available at www.pedig.net, and used to calculate a score for each participant and a separate treatment group mean for the three PedEyeQ domains of the Child, Proxy and Parent PedEyeQ at randomization and at each visit. Scores will also be converted to a 0-100 scale to aid in interpretation. Multiplicity adjusted two sided P-values and confidence intervals will be produced.; Child PedEyeQ: Functional Vision, Bothered by Eyes and Vision, Social, Frustration / Worry Proxy PedEyeQ: Functional Vision, Bothered by Eyes and Vision, Social, Frustration / Worry, Eyecare Parent PedEyeQ: Impact on Parent and Family, Worry about Child's Eye Condition, Worry about Self-perception and Interactions, Worry about Functional Vision	56 weeks
Secondary	Proportion Achieving Stable Resolved Outcome with Spectacles Alone	The proportion of participants in the Sequential Spectacles group who achieve "stable resolved" outcome status with spectacles alone will be calculated, along with a multiplicity adjusted two sided P-value and confidence interval.	56 Weeks
Secondary	Proportion of participants who achieve Binary distance visual acuity outcomes	The proportion of participants who achieve the following binary outcomes will be tabulated by treatment group to aid in the interpretation of the primary outcome: The proportion of participants with outcome amblyopic-eye distance VA improvement of = 2 logMAR lines (= 10 letters if E-ETDRS) from baseline.; The proportion of participants with stable resolved VA.; Poisson regression with the log link will be used to estimate the relative risk of each outcome for the sequential versus simultaneous and a multiplicity adjusted two sided P-value and confidence interval. The Poisson models will include an adjustment for baseline amblyopic eye VA.; In the event the number of outcomes is too small for reliable estimation with Poisson regression,43 a treatment group difference and 95% confidence interval will be estimated using the Farrington-Manning Score test or other exact method with no adjustment for baseline VA.	56 weeks
Secondary	Time to Stable Resolved Amblyopia	For those participants who are classified as "stable resolved," the time from baseline to the time meeting that classification will be compared between treatment groups, using a Kaplan-Meier analysis with the logrank test. Multiplicity adjusted two sided P-values and confidence intervals will be produced.	56 weeks
Secondary	Difference in Mean Change of Distance Visual Acuity after 8 Weeks on Randomized Treatment	An analysis of covariance (ANCOVA) will be performed to compute the difference in mean change in amblyopic-eye distance logMAR VA after 8 weeks between the sequential and simultaneous treatment groups, adjusted for baseline amblyopic eye distance VA, and a multiplicity adjusted two sided P-value and confidence interval will be constructed on the treatment group difference for each time point.	56 Weeks
Secondary	Change in binocularity levels	Binocularity will be assessed on an ordered scale combining the results of the Randot Preschool Test, Randot butterfly, and Worth 4-Dot (W4D) at near. Results of each individual test also will be tabulated at baseline and at the final study visit according to treatment group.; The possible levels of binocularity will be 40, 60, 100, 200, 400, 800 seconds of arc (Randot Preschool test), 2000 seconds of arc (Randot butterfly), binocular perception by W4D (4 or 5 lights), or no binocular perception by W4D (2 or 3 lights). This yields an ordered binocularity scale with 9 ordered levels. The change in binocularity levels for each test will be tabulated and compared between treatment groups using the exact Wilcoxon rank-sum test. The proportion of participants in each treatment group unable to perform testing will be tabulated but these participants will not be included in the analysis of change.	56 Weeks
Secondary	Difference in mean change in amblyopic-eye log contrast sensitivity	Contrast sensitivity scores range from unable (<0.90), and then from 0.90 to 2.05 (by 0.05 log contrast sensitivity units). An analysis of covariance (ANCOVA) will be performed to compute the difference in mean change in amblyopic-eye log contrast sensitivity units between the sequential and simultaneous treatment groups, adjusted for baseline amblyopic eye contrast sensitivity, and a multiplicity adjusted two sided P-value and confidence interval will be produced.	56 weeks